Physician profile
William C Paley
NPI 1124105754
$1,236.00
in general payments reported to CMS, 2019-2025
20 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.92 · 2020: $15.45 · 2021: $13.51 · 2022: $54.01 · 2023: $158 · 2024: $286 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.11 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $207.70 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Madrigal Pharmaceuticals | $185.03 | 2025 | Rezdiffra |
| Novo Nordisk INC | $152.67 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $113.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $80.21 | 2020-2024 | Bexsero, Shingrix, Arexvy |
| Hu-Friedy Mfg. Co., LLC | $57.00 | 2025 | Hu-Friedy Power Air & Piezo Unit |
| Redhill Biopharma INC. | $50.38 | 2025 | Talicia |
| Lilly USA, LLC | $49.49 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $46.04 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.55 | 2025 | Invega Sustenna |
| Regeneron Healthcare Solutions, INC. | $38.94 | 2024 | Dupixent |
| Phadia US INC. | $38.85 | 2023-2024 | Immunocap |
| Scilex Pharmaceuticals INC. | $34.68 | 2022 | |
| Alk-Abello, INC | $28.98 | 2025 | Neffy |
| Sanofi Pasteur INC. | $25.85 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.04 | 2024 | Thinprep 2000 Processor, Aptima |
| Viiv Healthcare Company | $21.32 | 2025 | Apretude |
| Amgen INC. | $16.74 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.61 | 2023 | Jardiance |
| Snap Diagnostics LLC | $11.29 | 2023 | Snap Diagnostics Study |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Paley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.